NCT06020573

Brief Summary

This monocentric early feasibility first in human study is intended to evaluate safety and performance of intraoperative detection of light signals during electrosurgical breast cancer resection. In consequence the data should also be taken to adapt technical features according to the findings. The study results will be utilized to design and to calculate the sample size for future pivotal studies after finalizing this study and to adapt the technical features of the system and/ or device. In the future pivotal study, the effectiveness of method and the reduction in R1 resection rate will be assessed with the final goal to provide continuous or real-time information about the tissue type that is currently cut. The primary endpoint for this first in human feasibility study is the percentage of patients with no serious adverse event related to the investigational device. After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. During the second visit (V2) they will receive the treatment procedure with the investigational medical device (IMD). The follow up visit (V3) will be performed up to 7 days after the treatment procedure at the day of discharge from the hospital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable breast-cancer

Timeline
Completed

Started Sep 2023

Shorter than P25 for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 24, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 31, 2023

Completed
26 days until next milestone

Study Start

First participant enrolled

September 26, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 29, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 29, 2024

Completed
Last Updated

September 5, 2024

Status Verified

September 1, 2024

Enrollment Period

10 months

First QC Date

August 24, 2023

Last Update Submit

September 2, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Safety, feasibility and performance

    The primary endpoint for this first in human feasibility study is the percentage of patients with no serious adverse event related to the investigational device.

    11 days

Study Arms (1)

Intraoperative detection of light signals during electrosurgical breast cancer resection

OTHER

Participants undergo electrosurgical breast cancer resection while light signals are detected intraoperatively

Device: Clip-on electrode with fiber optics

Interventions

The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.

Intraoperative detection of light signals during electrosurgical breast cancer resection

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female patient with primary invasive breast cancer (NST or NST with DCIS component, including endocrine pretreatment according to standard of care therapy at the study site)
  • Solid tumor size ≥ 15 mm at screening, on sonography imaging
  • Breast conserving surgery
  • ≥ 18 years of age
  • Ability to provide written informed consent

You may not qualify if:

  • Neoadjuvant chemotherapy
  • Bilateral breast conserving surgery
  • Invasive lobular carcinoma, DCIS, LCIS
  • Suspicion of extensive DCIS component of NST tumor
  • Diagnosis of recurrent breast cancer
  • Previous radiotherapy
  • Patient is pregnant or lactating
  • Patient is wearing active implant (cardiac pacemaker, internal defibrillator, other active implant), passive implants (hip arthroplasties, tooth implants etc.) are allowed at the discretion of the principal investigator
  • According to physicians' assessment, patient is not able to follow study protocol (e.g., due to cognitive disease) or is not able to understand the nature, objectives, benefits, implications, risks and inconveniences of the clinical investigation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department for Women's Health

Tübingen, 72076, Germany

Location

Related Publications (1)

  • Spether D, Scharpf M, Hennenlotter J, Schwentner C, Neugebauer A, Nussle D, Fischer K, Zappe H, Stenzl A, Fend F, Seifert A, Enderle M. Real-time tissue differentiation based on optical emission spectroscopy for guided electrosurgical tumor resection. Biomed Opt Express. 2015 Mar 24;6(4):1419-28. doi: 10.1364/BOE.6.001419. eCollection 2015 Apr 1.

    PMID: 25909025BACKGROUND

MeSH Terms

Conditions

Breast NeoplasmsMargins of Excision

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesMorphological and Microscopic FindingsPathological Conditions, Signs and Symptoms

Study Officials

  • Markus Hahn, Prof.Dr. Med.

    Department for Women's Health, Tuebingen, Germany

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2023

First Posted

August 31, 2023

Study Start

September 26, 2023

Primary Completion

July 29, 2024

Study Completion

July 29, 2024

Last Updated

September 5, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations